

# L3MBTL2 (E-16): sc-86512

## BACKGROUND

Polycomb group (PcG) proteins are important for maintaining the transcriptionally repressed state of target genes and are thought to function via chromatin modification. L3MBTL2 (Lethal(3)malignant brain tumor-like 2 protein), also known as L3MBT or H-I(3)mbt-l, is a 705 amino acid member of the PcG family. Localized to the nucleus, L3MBTL2 associates with chromatin-remodeling complexes and helps inhibit the expression of proteins that trigger the cell to enter mitosis. During the G<sub>0</sub> phase of the cell cycle, L3MBTL2 is part of a complex that contains other proteins (such as HP1 $\gamma$ , E2F-6 and Max) that participate in transcriptional repression. L3MBTL2 contains one FCS-type zinc finger and four MBT repeats and is expressed as three isoforms due to alternative splicing events.

## REFERENCES

- Dunham, I., et al. 1999. The DNA sequence of human chromosome 22. *Nature* 402: 489-495.
- Wismar, J. 2001. Molecular characterization of h-l(3)mbt-like: a new member of the human mbt family. *FEBS Lett.* 507: 119-121.
- Ogawa, H., et al. 2002. A complex with chromatin modifiers that occupies E2F- and Myc-responsive genes in G<sub>0</sub> cells. *Science* 296: 1132-1136.
- Online Mendelian Inheritance in Man, OMIM™. 2002. Johns Hopkins University, Baltimore, MD. MIM Number: 611865. World Wide Web URL: <http://www.ncbi.nlm.nih.gov/omim/>
- Markus, J., et al. 2003. Proliferation-linked expression of the novel murine gene m4mbt encoding a nuclear zinc finger protein with four mbt domains. *Gene* 319: 117-126.
- Li, J., et al. 2004. Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. *Proc. Natl. Acad. Sci. USA* 101: 7341-7346.

## CHROMOSOMAL LOCATION

Genetic locus: L3MBTL2 (human) mapping to 22q13.2.

## SOURCE

L3MBTL2 (E-16) is an affinity purified rabbit polyclonal antibody raised against a peptide mapping within an internal region of L3MBTL2 of human origin.

## PRODUCT

Each vial contains 100  $\mu$ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-86512 P, (100  $\mu$ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## PROTOCOLS

See our web site at [www.scbt.com](http://www.scbt.com) or our catalog for detailed protocols and support products.

## APPLICATIONS

L3MBTL2 (E-16) is recommended for detection of L3MBTL2 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2  $\mu$ g per 100-500  $\mu$ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).


Suitable for use as control antibody for L3MBTL2 siRNA (h): sc-75403, L3MBTL2 shRNA Plasmid (h): sc-75403-SH and L3MBTL2 shRNA (h) Lentiviral Particles: sc-75403-V.

Molecular Weight of L3MBTL2 isoforms: 79/69 kDa.

## RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use goat anti-rabbit IgG-HRP: sc-2004 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible goat anti-rabbit IgG-HRP: sc-2030 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunoprecipitation: use Protein A/G PLUS-Agarose: sc-2003 (0.5 ml agarose/2.0 ml). 3) Immunofluorescence: use goat anti-rabbit IgG-FITC: sc-2012 (dilution range: 1:100-1:400) or goat anti-rabbit IgG-TR: sc-2780 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

## DATA



L3MBTL2 (E-16): sc-86512. Western blot analysis of L3MBTL2 expression in 293T whole cell lysate.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.